Logo image of FDA.MI

FIDIA SPA (FDA.MI) Stock Analyst Earnings Estimates

BIT:FDA - Euronext Milan - IT0001498481 - Common Stock - Currency: EUR

0.0098  0 (-5.77%)

Full estimates are only available for subscribed users, you can see which data is available below.

Subscribed users also see more surprise data, now it is restricted to 4 quarters.

Examples of complete estimate data are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional estimates and surprises .

Yearly Revenue, EBIT, EBITDA and EPS Analyst Estimates
2021 2022 2023
Revenue
YoY % growth
FDA.MI revenue by date.FDA.MI revenue by date.
23.837M
12.23%
24.366M
2.22%
28.606M
17.40%
EBITDA
YoY % growth
FDA.MI ebitda by date.FDA.MI ebitda by date.
432K
116.41%
-2.3M
-632.41%
-164K
92.87%
EBIT
YoY % growth
FDA.MI ebit by date.FDA.MI ebit by date.
-1.501M
71.89%
-4.436M
-195.54%
-1.446M
67.40%
Operating Margin
FDA.MI operating margin by date.FDA.MI operating margin by date.
-6.30%-18.21%-5.05%
EPS
YoY % growth
FDA.MI eps by date.FDA.MI eps by date.
N/AN/AN/A

All data in EUR

Quarterly Revenue, EBIT, EBITDA and EPS Analyst Estimates
EPS
Q2Q % growth
Revenue
Q2Q % growth
EBITDA
Q2Q % growth
EBIT
Q2Q % growth

All data in EUR

Recent Earnings VS Estimates Surprises (EUR)
PeriodReportedEstimateDifferenceSurprise
FDA.MI Yearly EPS VS EstimatesFDA.MI Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 0.5 -0.5
Recent Revenue VS Estimates Surprises (EUR)
PeriodReportedEstimateDifferenceSurprise
Q2 2024
Q2Q % growth
9.421M
4.81%
%
Q4 2023
Q2Q % growth
19.617M
31.39%
%
Q2 2023
Q2Q % growth
8.989M
-4.74%
%
Q4 2020
Q2Q % growth
8.739M
-64.90%
%
Q2 2020
Q2Q % growth
12.5M
-40.15%
%
Q1 2020
Q2Q % growth
6.068M
-39.93%
%
FDA.MI Yearly Revenue VS EstimatesFDA.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M
EPS and Revenue Revisions
Next Q (1 month) Next Q (3 month) Next Year (1 month) Next Year (3 month)
EPSN/A N/A N/A N/A
RevenueN/A N/A N/A N/A